News

Goodbody Health Announces the Launch of Its Core Health Diagnostic Check

VANCOUVER, BC / ACCESSWIRE / May 26, 2022 / Goodbody Health Inc. (CSE:GDBY) (OTCQB:GDBYF) ("Goodbody Health" or the "Company") is…

2 years ago

Empower Clinics Granted Accreditation For Mobile Covid-19 Testing Solutions Throughout British Columbia

New Certification Makes Empower's Testing Solutions Even More Convenient for its CustomersVANCOUVER, BC / ACCESSWIRE / May 26, 2022 /…

2 years ago

Europe’s Leading Psychedelic Conference Returns to Amsterdam

The OPEN Foundation invites you to the Interdisciplinary Conference on Psychedelic Research this September, featuring the world’s best experts on…

2 years ago

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto’s oral galectin-3 inhibitor candidate, GB1211, reverses galectin-3 induced blockade of…

2 years ago

Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company committed…

2 years ago

WIMI Hologram Academy: Research and Application of Aircraft Component Assembly Technology Based on Virtual Reality

HONG KONG, May 26, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…

2 years ago

SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome

Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel TEL AVIV,…

2 years ago

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS…

2 years ago

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the…

2 years ago